trimetrexate has been researched along with Sarcoma in 6 studies
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
Sarcoma: A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.
| Excerpt | Relevance | Reference |
|---|---|---|
| " To better understand how ET-743 might be used clinically, the present study used SRB assays to examine the cytotoxicity resulting from combining ET-743 with three other antineoplastic agents: doxorubicin (DXR), trimetrexate, and paclitaxel in different administration schedules in two soft tissue sarcoma cell lines, HT-1080 and HS-18, in vitro." | 7.71 | Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells. ( Banerjee, D; Bertino, JR; Li, WW; Scotto, KW; Takahashi, N, 2001) |
| "A human fibrosarcoma cell line, HT-1080, and four new cell lines (HS-16, HS-28, HS-30, and HS-42) were established from untreated patients with mesenchymal chondrosarcoma, peripheral nerve sheath sarcoma, malignant hemangiopericytoma, and mixed mesodermal tumor, respectively, and were used for analysis of mechanisms of intrinsic resistance to methotrexate." | 7.68 | Intrinsic resistance to methotrexate in human soft tissue sarcoma cell lines. ( Bertino, JR; Li, WW; Lin, JT; Niedzwiecki, D; Schweitzer, BI; Tong, WP, 1992) |
| "Trimetrexate has shown promising activity in animal model systems." | 5.28 | Phase II trial of trimetrexate in patients with advanced soft-tissue sarcoma. ( Antman, KH; Gonin, R; Licht, JD, 1991) |
| " To better understand how ET-743 might be used clinically, the present study used SRB assays to examine the cytotoxicity resulting from combining ET-743 with three other antineoplastic agents: doxorubicin (DXR), trimetrexate, and paclitaxel in different administration schedules in two soft tissue sarcoma cell lines, HT-1080 and HS-18, in vitro." | 3.71 | Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells. ( Banerjee, D; Bertino, JR; Li, WW; Scotto, KW; Takahashi, N, 2001) |
| "A human fibrosarcoma cell line, HT-1080, and four new cell lines (HS-16, HS-28, HS-30, and HS-42) were established from untreated patients with mesenchymal chondrosarcoma, peripheral nerve sheath sarcoma, malignant hemangiopericytoma, and mixed mesodermal tumor, respectively, and were used for analysis of mechanisms of intrinsic resistance to methotrexate." | 3.68 | Intrinsic resistance to methotrexate in human soft tissue sarcoma cell lines. ( Bertino, JR; Li, WW; Lin, JT; Niedzwiecki, D; Schweitzer, BI; Tong, WP, 1992) |
| "Trimetrexate has shown promising activity in animal model systems." | 1.28 | Phase II trial of trimetrexate in patients with advanced soft-tissue sarcoma. ( Antman, KH; Gonin, R; Licht, JD, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (66.67) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| McMillin, DW | 1 |
| Hewes, B | 1 |
| Gangadharan, B | 1 |
| Archer, DR | 1 |
| Mittler, RS | 1 |
| Spencer, HT | 1 |
| Takahashi, N | 1 |
| Li, WW | 3 |
| Banerjee, D | 1 |
| Scotto, KW | 1 |
| Bertino, JR | 3 |
| Lin, JT | 2 |
| Tong, WP | 2 |
| Trippett, TM | 1 |
| Brennan, MF | 1 |
| Schweitzer, BI | 1 |
| Niedzwiecki, D | 1 |
| Licht, JD | 1 |
| Gonin, R | 1 |
| Antman, KH | 1 |
| Eisenhauer, EA | 1 |
| Wierzbicki, R | 1 |
| Knowling, M | 1 |
| Bramwell, VH | 1 |
| Quirt, IC | 1 |
6 other studies available for trimetrexate and Sarcoma
| Article | Year |
|---|---|
Complete regression of large solid tumors using engineered drug-resistant hematopoietic cells and anti-CD137 immunotherapy.
Topics: Adoptive Transfer; Animals; Antibodies; Antigens, CD; Antimetabolites, Antineoplastic; Bone Marrow T | 2006 |
Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Division; Dioxoles; Doxorubicin; Drug Synergism; Flow Cytomet | 2001 |
Mechanisms of natural resistance to antifolates in human soft tissue sarcomas.
Topics: Aminopterin; Chromatography, High Pressure Liquid; Drug Resistance; Folic Acid Antagonists; Humans; | 1992 |
Intrinsic resistance to methotrexate in human soft tissue sarcoma cell lines.
Topics: Drug Resistance; Humans; Methotrexate; Peptide Synthases; Polyglutamic Acid; Sarcoma; Soft Tissue Ne | 1992 |
Phase II trial of trimetrexate in patients with advanced soft-tissue sarcoma.
Topics: Antineoplastic Agents; Drug Evaluation; Folic Acid Antagonists; Humans; Infusions, Intravenous; Quin | 1991 |
Phase II trials of trimetrexate in advanced adult soft tissue sarcoma. Studies of the Canadian Sarcoma Group and the National Cancer Institute of Canada Clinical Trials Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Canada; Clinical Trials as Topic; Drug Administration Sc | 1991 |